🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  2. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  4. Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182

    Hoffmann-La Roche

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  5. Tecentriq 1 200 mg concentrate for solution for infusion, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  8. Tedizolid (BAY119-2631)

    Bayer HealthCare AG

    Bacterial Infections

    phase 3 small molecule completed

    1 trial

  9. Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)

    Eastern Hepatobiliary Surgery Hospital

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  10. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 3 small molecule terminated

    2 trials

  11. Telbivudine

    Novartis Pharmaceuticals

    Hepatitis

    phase 3 small molecule completed

    1 trial

  12. Telitacicept

    Vor Biopharma

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

  13. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  14. Tenecteplase

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  15. Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  16. Tenofovir DF

    Gilead Sciences Ireland UC

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  17. Tenofovir gel

    United Therapeutics Europe Ltd

    HIV Prevention

    phase 3 small molecule completed

    1 trial

  18. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  19. Teriparatide

    United Therapeutics Europe Ltd

    Stress Fracture

    phase 3 small molecule active

    1 trial

  20. Testosterone Gel 1%, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Bomba de gel transparente, donde la sustancia activa (testosterona) fue sustituida por agua purificada.

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    phase 3 small molecule active

    1 trial

  21. Testosterone enanthate

    HALOZYME THERAPEUTICS, INC.

    Hypogonadism, Male

    phase 3 other active

    1 trial

  22. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  23. Thalidomide

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  24. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources